EURETINA 2024: Subretinal gene therapy improves function and structure in patients with Bothnia Dystrophy

News
Article

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

Image credit: AdobeStock/Svitlana

(Image credit: AdobeStock/Svitlana)

Patients with Bothnia Dystrophy, a rare form of retinitis pigmentosa that causes legal blindness by early adulthood, benefited from subretinal administration of AAV8-RLBP1 gene therapy, which was considered safe and well tolerated, according to lead author Anders Kvanta, MD, from St. Erik Eye Hospital, Karolinska Institute, Stockholm, who discussed the findings at the 24th Euretina Congress in Barcelona.

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

Kvanta and colleagues conducted an open-label, dose-escalating, first-in-human, phase 1/2 study that included 12 patients with very delayed dark adaptation (DA) who received increasing subretinal AAV8-RLBP1 doses (5x109 to 1 x1011 vg/eye). Ocular and systemic safety; DA kinetics, the primary efficacy endpoint; and other light- and dark-adapted visual function measures were assessed.

Following overnight DA, recovery to full-field stimuli was assessed over 6 hours, Kvanta explained.

DA recovered with short-wavelength stimuli (450 nm) and improved in 8 of 12 patients 1 hour after bleaching light, 11 patients at 2 hours, and 9 patients at 3 hours. The improvements were sustained to the latest follow-up. Patients also reported improvement in daily activities. The prevalence of baseline punctata albescens decreased rapidly with the improved DA parameters in the treated eyes of 3 patients.

Other measures of light- and dark-adapted visual function (best-corrected visual acuity, contrast sensitivity, perimetry, and microperimetry) did not differ significantly.

The higher doses caused intraocular inflammation, which responded to steroids, and localized hyperpigmentation with retinal pigment epithelial atrophy.

AAV8-RLBP1, overall safe and well tolerated, showed long-lasting improvement in DA kinetics and anatomic phenotypes in these patients.

Reference
Kvanta A, Rangaswamy N, Holopigian K, et al. Sub-retinal gene therapy improves function and structure in patients with Bothnia Dystrophy. Presented at the 24th Euretina Congress, Barcelona, Spain. Session: Free Paper 12 Inherited Retinal Diseases

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.